Trial
NCT00994253
Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
Phase IVWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Corewell Health East
Collaborators
Novartis Pharmaceuticals
Condition
Hypertension
Intervention
Aliskiren
Why stopped
Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-02